These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23224484)

  • 1. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis.
    de Gusmao CM; Ortega MR; Wallace DM
    J Neuropsychiatry Clin Neurosci; 2012; 24(4):E47-8. PubMed ID: 23224484
    [No Abstract]   [Full Text] [Related]  

  • 2. Dalfampridine (Ampyra) for MS.
    Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716
    [No Abstract]   [Full Text] [Related]  

  • 3. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Panicucci E; Cohen M; Bourg V; Rocher F; Thomas P; Lebrun C
    Mult Scler; 2019 Apr; 25(4):618-621. PubMed ID: 30375922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalfampridine: is the seizure risk greater than previously thought?
    Farag A; Averill A
    Am J Phys Med Rehabil; 2013 Jul; 92(7):635-6. PubMed ID: 23051757
    [No Abstract]   [Full Text] [Related]  

  • 5. 10 questions about 4-aminopyridine and the treatment of multiple sclerosis.
    Bever CT
    Neurologist; 2009 May; 15(3):161-2. PubMed ID: 19430274
    [No Abstract]   [Full Text] [Related]  

  • 6. 4-aminopyridine: new life for an old drug.
    Hauser SL; Johnston SC
    Ann Neurol; 2010 Jul; 68(1):A8-9. PubMed ID: 20583227
    [No Abstract]   [Full Text] [Related]  

  • 7. Dalfampridine in multiple sclerosis.
    Goodman AD; Hyland M
    Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
    Hussar DA; Kaczinski J
    J Am Pharm Assoc (2003); 2010; 50(3):436-9. PubMed ID: 20452924
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis.
    Burton JM; Bell CM; Walker SE; O'Connor PW
    Neurology; 2008 Nov; 71(22):1833-4. PubMed ID: 19029525
    [No Abstract]   [Full Text] [Related]  

  • 11. Dalfampridine prior authorization program: a cohort study.
    Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
    J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalfampridine (Ampyra) for multiple sclerosis.
    Belavic JM
    Nurse Pract; 2010 Nov; 35(11):7-9. PubMed ID: 20975442
    [No Abstract]   [Full Text] [Related]  

  • 13. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalfampridine approved for MS.
    Traynor K
    Am J Health Syst Pharm; 2010 Mar; 67(5):335. PubMed ID: 20172978
    [No Abstract]   [Full Text] [Related]  

  • 16. [Aminopyridines for symptomatic treatment of multiple sclerosis].
    Jensen HB; Stenager E; Ravnborg MH
    Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy and safety of fampridine.
    Mejuto B; Castellano P; Castro C; López LM
    Farm Hosp; 2017 Mar; 41(2):283-291. PubMed ID: 28236802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing dalfampridine efficacy in the physician's office.
    Raffel JB; Malik O; Nicholas RS
    Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].
    Husseini L; Leussink VI; Kieseier BC; Hartung HP
    Nervenarzt; 2010 Feb; 81(2):203-11. PubMed ID: 20112006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.